Drugs Containing Excipient (Inactive Ingredient) SUCRALOSE

« Back to Dashboard

Branded drugs containing SUCRALOSE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
L Perrigo Company	GOOD SENSE LANSOPRAZOLE	lansoprazole	0113-0116	SUCRALOSE
L Perrigo Company	GOOD SENSE OMEPRAZOLE	omeprazole	0113-0520	SUCRALOSE
L Perrigo Company	GOOD SENSE OMEPRAZOLE	omeprazole	0113-1723	SUCRALOSE
L Perrigo Company	GOOD SENSE OMEPRAZOLE DELAYED RELEASE	omeprazole	0113-1803	SUCRALOSE
L Perrigo Company	BASIC CARE LANSOPRAZOLE	lansoprazole	0113-7116	SUCRALOSE
L Perrigo Company	BASIC CARE OMEPRAZOLE	omeprazole	0113-7401	SUCRALOSE

Generic drugs containing SUCRALOSE excipient

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	buprenorphine hydrochloride and naloxone hydrochloride dihydrate	0054-0188	SUCRALOSE
Hikma Pharmceuticals USA Inc	oxycodone hydrochloride	0054-0390	SUCRALOSE
Hikma Pharmaceuticals USA Inc	clobazam	0054-0561	SUCRALOSE
Hikma Pharmaceuticals USA Inc	tofacitinib	0054-0821	SUCRALOSE
L Perrigo Company	nicotine polacrilex	0113-0053	SUCRALOSE
L Perrigo Company	lansoprazole	0113-0116	SUCRALOSE

Sucralose Pharmaceutical Excipient Market: Dynamics, Pricing, Supply Chain, and Financial Trajectory

Last updated: October 13, 2026

Sucralose is a high-intensity sweetener used in pharmaceutical oral liquids, chewable tablets, orally disintegrating tablets, powders, and nutritional products. The pharmaceutical excipient segment is materially smaller than the food and beverage market, which determines global production economics, supplier capacity, and pricing.

The market has four defining characteristics:

1. Pharmaceutical demand is growing with pediatric medicines, geriatric formulations, nutraceuticals, and taste-masked oral dosage forms.
2. Food and beverage demand remains the primary volume driver.
3. Manufacturing is concentrated in China, creating price competition but also supply-chain and qualification risk.
4. The original composition-of-matter patent position no longer provides meaningful exclusivity. Current competitive barriers are regulatory qualification, consistent impurity control, process know-how, customer approvals, and supply reliability.

Public companies generally do not disclose standalone sucralose revenue. Market-size figures therefore rely on third-party estimates and should be treated as directional rather than audited financial data.

What is the pharmaceutical excipient market for sucralose?

Sucralose is a chlorinated sucrose derivative with approximately 600 times the sweetness of sucrose. In pharmaceuticals, it is primarily a taste-masking and palatability excipient rather than an active pharmaceutical ingredient.

The largest pharmaceutical applications are:

Application	Role of sucralose	Commercial relevance
Oral liquids	Sweetness and taste masking	High, particularly in pediatric products
Chewable tablets	Palatability improvement	High
Orally disintegrating tablets	Sweetness after rapid dissolution	Moderate to high
Granules and powders	Flavor correction	Moderate
Effervescent products	Sweetness and flavor balance	Moderate
Nutraceuticals	Taste masking in powders and gummies	High
Topical and parenteral products	Limited use	Low

Pharmaceutical demand is usually sold as a qualified excipient grade with tighter specifications, documentation, traceability, and change-control requirements than food-grade material. The chemical identity is the same, but customer qualification requirements can differ substantially.

The pharmaceutical segment is likely a low-single-digit share of total global sucralose volume. Its value share is higher than its volume share because pharmaceutical customers generally pay for documentation, lot consistency, testing, and supply assurance.

How large is the global sucralose market?

Third-party market studies generally place the total global sucralose market in the high hundreds of millions to approximately $1 billion range in the early 2020s. Published estimates vary because some reports include branded products, blends, and downstream sweetener systems, while others measure only bulk sucralose.

Market indicator	Directional assessment
Total global sucralose market, early 2020s	Approximately $0.7 billion to $1.2 billion
Expected medium-term growth	Approximately 4% to 8% annually
Pharmaceutical share of total volume	Likely low single digits
Pharmaceutical share of total value	Higher than volume share
Main volume market	Food and beverages
Main growth markets	Asia-Pacific, Latin America, pediatric and nutraceutical products

Third-party estimates from Grand View Research and Fortune Business Insights identify continued growth in low-calorie sweeteners, processed foods, beverages, dietary products, and pharmaceutical formulations. Their methodologies and market definitions differ, so the figures should not be combined into a single precise market value (Fortune Business Insights, 2024; Grand View Research, 2024).

The pharmaceutical excipient opportunity is narrower than the total market but has better customer retention. Once a pharmaceutical manufacturer validates a supplier, replacing the source can require method validation, stability work, regulatory documentation, and sometimes a post-approval change submission.

What is driving sucralose demand in pharmaceuticals?

Pediatric medicines

Pediatric oral liquids often require substantial taste correction. Sucralose is attractive because it delivers strong sweetness at low concentrations and has broad compatibility with liquid formulations.

Demand is supported by:

• Antibiotic suspensions
• Analgesic and antipyretic liquids
• Cough and cold products
• Allergy medicines
• Vitamin and mineral formulations
• Chronic pediatric therapies

Formulators often combine sucralose with flavors, polyols, acids, buffers, and other sweeteners. Sucralose can reduce the amount of bulk sugar required and avoid the caloric contribution of sucrose.

Orally disintegrating and chewable dosage forms

Taste is a principal development constraint for orally disintegrating and chewable products. Sucralose is used when a formulator needs strong sweetness without materially increasing tablet mass.

Its use is strongest where:

• The active ingredient is bitter or metallic tasting.
• The tablet dissolves rapidly in the mouth.
• The product targets children or older patients.
• Sugar reduction is commercially relevant.
• A low-dose sweetener is preferred over high-load polyols.

Nutraceutical and consumer-health products

Powdered supplements, gummies, effervescent products, and liquid nutritional products create overlap between pharmaceutical-grade and food-grade demand. This channel can provide volume growth, but it is more exposed to consumer preferences concerning artificial sweeteners.

Reformulation and sugar reduction

Manufacturers continue to reduce sucrose, glucose, and caloric content in oral products. Sucralose can support this transition, although some developers use steviol glycosides, acesulfame potassium, aspartame, saccharin, or newer sweetener systems instead.

How does sucralose compare with other pharmaceutical sweeteners?

Sucralose competes on sweetness intensity, taste profile, regulatory history, compatibility, and formulation cost.

Sweetener	Relative strength	Pharmaceutical advantages	Main limitations
Sucralose	About 600 times sucrose	High intensity, low use level, broad oral use	Artificial-sweetener perception; supplier concentration
Aspartame	About 200 times sucrose	Familiar taste, established use	Phenylalanine labeling and stability constraints
Acesulfame potassium	About 200 times sucrose	Heat stability and low use level	Aftertaste in some formulations
Saccharin sodium	About 300 to 500 times sucrose	Low cost and high intensity	Metallic or bitter aftertaste
Steviol glycosides	Varies by grade	Plant-derived positioning	Bitterness and formulation variability
Sorbitol	About 0.6 times sucrose	Bulk, mouthfeel, cooling effect	Gastrointestinal effects at higher exposure
Xylitol	Similar to sucrose	Dental positioning and cooling effect	Higher cost and gastrointestinal tolerance limits
Sucrose	Reference standard	Familiar taste and bulk	Caloric load and microbial/stability considerations

Sucralose is strongest when a product needs intense sweetness at low loading and the formulator accepts a synthetic sweetener. It is less differentiated in products marketed around natural or clean-label positioning.

What FDA regulatory status does sucralose have?

The U.S. Food and Drug Administration approved sucralose for use as a food additive in 1998 and permits its use under 21 C.F.R. § 172.831. The regulation specifies permitted uses and conditions for use in foods and beverages, including use as a nonnutritive sweetener (U.S. Food and Drug Administration, 1998).

Pharmaceutical use depends on the individual product formulation, route, dosage form, and applicable inactive-ingredient requirements. Sucralose is listed in the FDA Inactive Ingredient Database for certain drug products and dosage forms, but the database does not create blanket approval for every formulation or route.

In the European Union, sucralose is identified as food additive E955. Pharmaceutical manufacturers separately rely on excipient quality, product-specific regulatory filings, and applicable European Pharmacopoeia requirements.

Safety and acceptable daily intake

The FDA established an acceptable daily intake of 5 milligrams per kilogram of body weight per day for sucralose. The Joint FAO/WHO Expert Committee on Food Additives established an ADI of 0 to 15 milligrams per kilogram of body weight per day. EFSA has also evaluated sucralose in the context of permitted food uses and exposure (U.S. Food and Drug Administration, 1998; Joint FAO/WHO Expert Committee on Food Additives, 1991; European Food Safety Authority, 2011).

These limits apply to systemic exposure assessments and permitted use conditions. A pharmaceutical developer must still assess total daily exposure when sucralose is present in multiple products or administered at high frequency.

What pharmaceutical formulations are protected by sucralose-related patents?

The broad chemical composition of sucralose is not the primary source of current commercial exclusivity. Original composition and manufacturing patents have largely expired or have limited remaining practical value in major markets.

Current intellectual-property protection is more likely to involve:

• Specific oral liquid compositions
• Taste-masked active pharmaceutical ingredients
• Sucralose combined with flavors or bitterness suppressors
• Orally disintegrating tablet matrices
• Effervescent formulations
• Stabilized formulations
• Controlled-release dosage forms
• Manufacturing and purification processes
• Impurity-control methods
• Specific therapeutic methods using a formulation containing sucralose

A formulation patent can protect a finished drug product even when sucralose itself is off-patent. The value depends on claim breadth, enablement, prior art, design-around options, and whether the formulation is listed in the Orange Book.

What is the Orange Book status of sucralose?

Sucralose itself is not an FDA-approved active drug and does not have an independent Orange Book listing. The Orange Book lists approved drug products, their active ingredients, therapeutic equivalence information, and applicable patents or exclusivity.

A sucralose-containing drug may have Orange Book-listed patents if the approved product has a qualifying formulation, method-of-use, drug-delivery, or other patent. The listing would attach to the finished drug product, not to sucralose as a standalone excipient.

This distinction matters for generic competition. A generic applicant generally challenges patents covering the reference drug product, not the expired status of the sweetener.

When does sucralose lose exclusivity?

Sucralose has no meaningful current regulatory exclusivity as an excipient. Its commercial position is based on market authorization, manufacturing capability, customer qualification, and quality systems.

Exclusivity category	Current position
Active ingredient exclusivity	Not applicable
FDA new chemical entity exclusivity	Not applicable to sucralose as an excipient
Orange Book exclusivity	Not applicable to bulk sucralose
Broad composition patent	Generally expired or commercially immaterial
Process patents	May remain relevant for specific manufacturing routes
Formulation patents	May protect particular finished drugs
Regulatory exclusivity for a finished product	Depends on the active drug, not sucralose

Patent expiration dates must therefore be assessed at the level of the finished pharmaceutical product or the supplier’s manufacturing process. There is no single “sucralose patent expiration date” that controls the entire market.

How many suppliers manufacture pharmaceutical-grade sucralose?

The global supplier base is concentrated but not monopolistic. China is the central manufacturing hub, with producers supplying food, beverage, nutrition, and pharmaceutical customers. Global suppliers and distributors include Chinese manufacturers, multinational sweetener companies, and specialty excipient distributors.

The competitive field generally includes:

• Jiangsu Niutang Chemical Plant
• Anhui Jinhe Industrial
• JK Sucralose and affiliated Chinese producers
• Tate & Lyle-related commercial channels and distributors
• Regional specialty excipient distributors
• Contract and private-label suppliers

Corporate ownership, production arrangements, and distribution relationships change over time. Purchasers should distinguish between the original manufacturer, the registered supplier, and the distributor named in the pharmaceutical quality agreement.

Manufacturing barriers

The chemistry is established, but consistent large-scale production requires control of:

• Chlorination and reaction conditions
• Intermediate conversion
• Residual solvents
• Related substances
• Chlorinated organic impurities
• Heavy metals and elemental impurities
• Microbial quality
• Particle-size distribution
• Moisture and storage stability
• Batch-to-batch sweetness and assay

Pharmaceutical customers also expect audit access, deviation handling, change notification, data integrity, and validated analytical methods. These requirements create a stronger barrier than the basic chemistry.

What is the pricing and margin trajectory for sucralose?

Sucralose pricing has faced downward pressure from expanded Chinese capacity, intense supplier competition, and food-industry purchasing discipline. Prices can move sharply when capacity utilization changes or when major buyers reduce inventories.

The commercial trajectory can be summarized as follows:

Period	Market dynamic	Financial effect
2018-2020	Stable demand with growing beverage and nutrition use	Generally supportive pricing
2020-2021	Pandemic-related logistics disruption and uneven demand	Higher freight and inventory volatility
2022	Input-cost inflation and supply-chain normalization	Mixed pricing; cost pressure
2023-2024	Capacity competition and softer industrial pricing in China	Margin pressure for commodity suppliers
2025 onward	Moderate demand growth with ongoing oversupply risk	Volume growth may outpace price growth

Pharmaceutical-grade material can command a premium over standard food-grade material, but the premium is not unlimited. Large pharmaceutical buyers often negotiate formula-based pricing, dual-source arrangements, annual reductions, and audit rights.

The best margins generally accrue to suppliers with:

• Validated pharmaceutical customer accounts
• Strong regulatory documentation
• Reliable supply during shortages
• Low impurity variability
• Regional inventory
• Technical support
• Multi-year supply contracts

Commodity producers with limited documentation remain exposed to price competition and customer switching.

What is the financial trajectory for sucralose manufacturers?

Standalone revenue and EBITDA data for sucralose are generally unavailable. Public companies report broader sweetener, food-ingredient, or chemical segments rather than sucralose-specific financials.

The financial outlook has three layers:

Volume growth

Demand should expand with:

• Low-calorie beverages
• Sugar-reduced foods
• Pediatric medicines
• Nutraceuticals
• Oral dosage forms requiring taste masking
• Emerging-market consumption

Price and margin pressure

Volume growth does not necessarily translate into equivalent revenue growth. Expanded capacity and competition among Chinese suppliers can reduce average selling prices. A market growing at 5% to 7% by volume could produce materially lower revenue growth if pricing declines.

Mix improvement

Pharmaceutical and high-specification nutrition applications support better pricing and customer retention than bulk beverage applications. Suppliers that shift toward documented pharmaceutical grades may improve gross margin even if total market prices remain under pressure.

A reasonable base-case financial profile is:

Metric	Base-case direction
Global volume	Mid-single-digit growth
Total market revenue	Low- to mid-single-digit growth
Commodity pricing	Flat to declining
Pharmaceutical-grade pricing	More stable than food-grade pricing
Supplier margins	Under pressure without qualification or differentiation
Working capital	Elevated when customers destock
Capital expenditure	Focused on purification, quality systems, and capacity efficiency

Which companies are challenging the established sucralose supply base?

Competition comes mainly from:

• Chinese producers adding or optimizing capacity
• Alternative high-intensity sweetener manufacturers
• Stevia and monk-fruit suppliers
• Formulation companies using sweetener combinations
• Pharmaceutical excipient distributors offering dual-source programs

The main competitive threat is substitution rather than patent litigation. A drug developer can replace sucralose with another sweetener if taste, stability, labeling, exposure, and regulatory requirements are acceptable. The switching cost is higher for approved medicines because reformulation can require stability studies and regulatory filings.

What litigation and settlement risks affect sucralose?

Sucralose is not generally associated with the type of Orange Book patent litigation seen in branded pharmaceuticals. The main legal risks are more likely to involve:

• Trade-secret claims
• Manufacturing-process disputes
• Supplier exclusivity agreements
• Quality and contamination claims
• Product liability
• Labeling and regulatory claims
• Patent disputes over specific formulations or production processes

Settlement agreements are therefore more likely to arise in commercial supply, licensing, or formulation disputes than in Paragraph IV litigation concerning sucralose itself.

Paragraph IV risk can arise indirectly when a generic drug applicant challenges a patent covering a finished drug that uses sucralose. The challenge would target the listed drug patent, not the excipient’s market authorization.

What generic entry risks exist for sucralose-containing drugs?

Generic entry risk depends on the finished product.

A conventional immediate-release tablet using sucralose as a minor excipient generally has limited ability to preserve exclusivity through the sweetener alone. Greater protection may exist where sucralose is part of:

• A narrow taste-masking system
• A specific orally disintegrating matrix
• A complex pediatric liquid
• A stability-critical formulation
• A combination of sweeteners and flavoring agents
• A patented delivery platform

Generic applicants may design around a formulation patent by using another sweetener, a different flavor system, or another taste-masking technology. The strength of protection depends on whether the patent claims the presence of sucralose specifically or claims broader functional characteristics.

What geographic markets have the strongest growth prospects?

Asia-Pacific is the largest manufacturing center and one of the strongest consumption-growth regions. China combines production scale, food and beverage demand, pharmaceutical manufacturing, and export capacity.

North America remains commercially important because of branded beverages, dietary products, pharmaceuticals, and established regulatory acceptance. Europe has substantial demand but faces stronger scrutiny from consumers and regulators over artificial sweeteners and food exposure.

Region	Opportunity	Primary risk
China	Production scale and domestic demand	Oversupply and price competition
India	Pharmaceutical manufacturing and generic medicines	Price sensitivity and qualification complexity
North America	Mature pharmaceutical and beverage markets	Stable or slower volume growth
Europe	Specialty formulations and regulated pharmaceutical demand	Consumer preference and regulatory scrutiny
Latin America	Beverage and pharmaceutical growth	Currency, logistics, and distributor dependence
Middle East and Africa	Expanding processed-food and medicine demand	Import dependence and registration complexity

How strong is the sucralose patent estate?

The patent estate is weak for the basic excipient and stronger for selected applications.

IP layer	Strength	Commercial implication
Basic sucralose composition	Low	Broad market access
Legacy production patents	Low to moderate	Some process-specific relevance
Modern purification processes	Moderate	May support supplier differentiation
Pharmaceutical formulation patents	Moderate to strong in narrow claims	Can delay generic substitution
Taste-masking combinations	Moderate	Design-around risk is material
Manufacturing trade secrets	Moderate to strong	Difficult to evaluate externally
Supplier know-how and quality systems	High practical value	Supports customer retention

The highest-value moat is operational rather than patent-based. A supplier that consistently meets pharmaceutical specifications, maintains regulatory files, and passes customer audits can retain business even when lower-priced material is available.

Key Takeaways

• Sucralose is a mature, off-patent excipient with growing pharmaceutical use.
• Food and beverage demand controls global capacity and pricing.
• Pharmaceutical applications provide better margins and retention than commodity uses.
• China is the dominant manufacturing base, creating both scale advantages and oversupply risk.
• Public companies do not generally disclose standalone sucralose revenue.
• Total market estimates typically fall in the high hundreds of millions to approximately $1 billion, depending on scope.
• Medium-term volume growth is likely in the mid-single digits, while pricing may remain under pressure.
• Sucralose has no independent Orange Book exclusivity.
• Patent value is concentrated in finished formulations, taste-masking systems, and manufacturing processes.
• The strongest commercial defenses are supplier qualification, quality consistency, documentation, and reliable delivery.

FAQs

Is sucralose considered a pharmaceutical excipient?

Yes. Sucralose is used as a sweetening and taste-masking excipient in oral pharmaceutical products, including liquids, chewable tablets, orally disintegrating tablets, and powders.

Is pharmaceutical-grade sucralose different from food-grade sucralose?

The chemical substance is the same, but pharmaceutical-grade supply generally requires more extensive documentation, testing, traceability, change control, and customer qualification.

Does sucralose have an Orange Book patent?

No independent Orange Book patent protects bulk sucralose. A finished drug containing sucralose may have Orange Book-listed patents covering its formulation, delivery system, or method of use.

Can a generic drug replace sucralose with another sweetener?

Usually, subject to product specifications and regulatory requirements. The generic applicant may use a different sweetener if it can meet performance, stability, safety, labeling, and bioequivalence requirements.

Is sucralose manufacturing economically attractive?

It can be attractive for suppliers with scale, low production costs, qualified pharmaceutical customers, and strong quality systems. Commodity margins are vulnerable to Chinese capacity expansion and price competition.

References

1. European Food Safety Authority. (2011). Scientific opinion on the re-evaluation of sucralose (E 955) as a food additive. EFSA Journal, 9(5), 2180.

2. Fortune Business Insights. (2024). Sucralose market size, share and industry analysis. Fortune Business Insights.

3. Grand View Research. (2024). Sucralose market size, share and trends analysis report. Grand View Research.

4. Joint FAO/WHO Expert Committee on Food Additives. (1991). Evaluation of certain food additives and contaminants: Thirty-seventh report of the Joint FAO/WHO Expert Committee on Food Additives. World Health Organization.

5. U.S. Food and Drug Administration. (1998). Sucralose: 21 C.F.R. § 172.831. U.S. Department of Health and Human Services.

6. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. U.S. Department of Health and Human Services.